Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Telo Genomics Corp TDSGF


Primary Symbol: V.TELO

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display... see more

Recent & Breaking News (TSXV:TELO)

Telo Genomics Announces Successful Validation of Its Proprietary Automation Tools for Smoldering Multiple Myeloma

Newsfile May 31, 2022

Telo Genomics Announces Investor Relations Agreement and Option Grants

Newsfile March 15, 2022

Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test

Newsfile March 7, 2022

Telo Genomics (TSXV:TELO) appoints Dr. McGlennen as Board Director

Brieanna McCutcheon  February 3, 2022

Telo Genomics Appoints Dr. McGlennen as Board Director, a Leader in Commercializing Novel Diagnostic Technologies

Newsfile February 3, 2022

Telo Genomics (TSXV:TELO) advances lead product and Implements automation to workflow

Caroline Egan  January 19, 2022

Telo Genomics Advances Its Lead Product and Implements Automation to Its Workflow

Newsfile January 19, 2022

Telo Genomics (TSXV:TELO) announces OTCQB Venture Market listing

John Ballem  December 7, 2021

Telo Genomics Announces OTCQB Venture Market Listing

Newsfile December 7, 2021

Telo Genomics Announces the Outcome of its Participation in the International Myeloma Workshop and Clinical Studies Progress

Newsfile October 13, 2021

Telo Genomics Adopts Advanced Notice Provisions in By-Laws

Newsfile October 5, 2021

Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital

Newsfile September 21, 2021

Telo Genomics (TSXV:TELO) participates in the 18th International Myeloma Society Workshop 2021

Brieanna McCutcheon  September 9, 2021

Telo Genomics Participates in the 18th International Myeloma Society Workshop 2021

Newsfile September 9, 2021

Telo Genomics Engages Clinical and Regulatory Affairs Veteran to Lead the Company's ISO 15189 Certification & CLIA Laboratory Accreditation Undertaking

Newsfile August 9, 2021

Telo Genomics (TSXV:TELO) completes final tranche of private placementTelo Genomics (TSXV:TELO) completes final tranche of private placement

Trevor Abes  July 5, 2021

Telo Genomics Completes Final Tranche of Oversubscribed Private Placement

Newsfile July 5, 2021

Telo Genomics (TSXV:TELO) completes first tranche of private placement

John Ballem  July 2, 2021

Telo Genomics Completes First Tranche of Oversubscribed Private Placement

Newsfile July 2, 2021

Telo Genomics (TSXV:TELO) announces private placement financing

John Ballem  June 18, 2021